CoChat

Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-sectional Survey

Open access
Sherr, Jennifer L., Laffel, Lori M., Liu, Jingwen, Wolf, Wendy, Bispham, Jeoffrey, Chapman, Katherine S., Finan, Daniel, Titievsky, Lina, Liu, Tina, Hagan, Kaitlin, Gaglia, Jason, Chandarana, Keval, Bergenstal, Richard, Pettus, Jeremy · 2024 · Diabetes Care

Published version of a preprint

Cited by 99

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To determine how diabetes technologies, including continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems, impact glycemic metrics, prevalence of severe hypoglycemic events (SHEs), and impaired awareness of hypoglycemia (IAH) in people with type 1 diabetes in a real-world setting within the U.S. RESEARCH DESIGN AND METHODS: In this retrospective, observational study with cross-sectional elements, participants aged ≥18 years were enrolled from the T1D Exchange Registry/online community. Participants completed a one-time online survey describing glycemic metrics, SHEs, and IAH. The primary objective was to determine the proportions of participants who reported achieving glycemic targets (assessed according to self-reported hemoglobin A1c) and had SHEs and/or IAH. We performed additional subgroup analyses focusing on the impact of CGM and insulin delivery modality. RESULTS: A total of 2,074 individuals with type 1 diabetes were enrolled (mean ± SD age 43.0 ± 15.6 years and duration of type 1 diabetes 26.3 ± 15.3 years). The majority of participants (91.7%) were using CGM, with one-half (50.8%) incorporating AID. Despite high use of diabetes technologies, only 57.7% reported achieving glycemic targets (hemoglobin A1c <7%). SHEs and IAH still occurred, with ∼20% of respondents experiencing at least one SHE within the prior 12 months and 30.7% (95% CI 28.7, 32.7) reporting IAH, regardless of CGM or AID use. CONCLUSIONS: Despite use of advanced diabetes technologies, a high proportion of people with type 1 diabetes do not achieve glycemic targets and continue to experience SHEs and IAH, suggesting an ongoing need for improved treatment strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc23-1765

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 14

  1. Holt, 2021, The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, 64, 2609, 10.1007/s00125-021-05568-3 · DOI · Paper page
  2. Renard, 2021, The SAGE study: global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM, Diabetes Metab Res Rev, 37, e3430, 10.1002/dmrr.3430 · DOI · Paper page
  3. Amiel, 2021, The consequences of hypoglycaemia, Diabetologia, 64, 963, 10.1007/s00125-020-05366-3 · DOI · Paper page
  4. Cryer, 2014, Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia, Diabetes, 63, 2188, 10.2337/db14-0059 · DOI · Paper page
  5. Shah, 2018, Severe hypoglycemia is associated with high risk for falls in adults with type 1 diabetes, Arch Osteoporos, 13, 66, 10.1007/s11657-018-0475-z · DOI
  6. Moser, 2023, Impact of severe hypoglycaemia requiring hospitalization on mortality in people with type 1 diabetes: a national retrospective observational cohort study, Diabetes Obes Metab, 25, 2243, 10.1111/dom.15102 · DOI
  7. Cryer, 2012, Severe hypoglycemia predicts mortality in diabetes, Diabetes Care, 35, 1814, 10.2337/dc12-0749 · DOI · Paper page
  8. Gold, 1994, Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia, Diabetes Care, 17, 697, 10.2337/diacare.17.7.697 · DOI · Paper page
  9. Geddes, 2008, Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes, Diabet Med, 25, 501, 10.1111/j.1464-5491.2008.02413.x · DOI · Paper page
  10. Yu, 2023, Prevalence of impaired awareness of hypoglycaemia in people with diabetes mellitus: A systematic review and meta-analysis from 21 countries and regions, Diabet Med, 40, e15129, 10.1111/dme.15129 · DOI
  11. McCall, 2023, Management of individuals with diabetes at high risk for hypoglycemia: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 108, 529, 10.1210/clinem/dgac596 · DOI · Paper page
  12. Gavin, 2021, Real-world studies support use of continuous glucose monitoring in type 1 and type 2 diabetes independently of treatment regimen, Diabetes Technol Ther, 23, S19, 10.1089/dia.2021.0211 · DOI
  13. Farrell, 2021, Clinical approaches to treat impaired awareness of hypoglycaemia, Ther Adv Endocrinol Metab, 12, 20420188211000248, 10.1177/20420188211000248 · DOI · Paper page
  14. Kraaijeveld, 2021, Continuous glucose monitoring as a matter of justice, HEC Forum, 33, 345, 10.1007/s10730-020-09413-9 · DOI

Cited by

See all 99

Metadata

Authors
Sherr, J. L., Laffel, L. M., Liu, J., Wolf, W., Bispham, J., Chapman, K. S., Finan, D., Titievsky, L., Liu, T., Hagan, K., Gaglia, J., Chandarana, K., Bergenstal, R., & Pettus, J.
Venue
Diabetes Care
Published
2024-01-31
Volume
47
Issue
6
Pages
941-947
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W4391378998
Cited by
99
References
13
FWCI
26.90
Type
journal article
Language
en
Open access
bronze
Funders
Vertex Pharmaceuticals Incorporated

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.